BC Week In Review | Feb 14, 2011
Clinical News

BIO-11006 Inhalation Solution: Phase IIa data

The double-blind, U.S. Phase IIa BREATH 1 trial in 172 patients with moderately severe COPD showed that twice-daily 75 mg BIO-11006 missed the primary endpoint of significantly improving FEV1 from baseline to day 21 vs....
BC Week In Review | Apr 27, 2009
Clinical News

BIO-11006 Inhalation Solution: Phase II ongoing

BioMarck said an independent safety monitoring committee recommended continuation of the double-blind, placebo-controlled, U.S. Phase II BREATH-1 trial based on a review of safety data from the first 75 mg dose group. The company will...
BC Week In Review | Jul 7, 2008
Clinical News

BIO-11006 Inhalation Solution: Phase II started

BioMarck began the double-blind, placebo-controlled, U.S. Phase II BREATH-1 trial to evaluate 75, 150 or 250 mg of inhaled BIO-11006 given once daily for 3 weeks in 162 patients. BioMarck Pharmaceuticals Ltd. , Raleigh, N.C.  ...
BC Week In Review | Feb 11, 2008
Clinical News

BIO-11006 Inhalation Solution: Phase I data

In a double-blind, placebo-controlled Phase I trial (BIM-CL-002) in 59 volunteers, single and multiple doses of BIO-11006 were safe and well tolerated. The company plans to begin a Phase II trial in COPD patients with...
BC Week In Review | Feb 11, 2008
Clinical News

BIO-11006 Inhalation Solution: Phase I data

In a double-blind, placebo-controlled Phase I trial (BIM-CL-001) in 8 volunteers, single doses of BIO-11006 were safe and well tolerated. The company plans to begin a Phase II trial in COPD patients with chronic bronchitis...
BC Week In Review | Oct 22, 2007
Clinical News

BIO-11006 inhalation Solution: Phase II start

Next quarter, BioMarck will begin a Phase II trial. BioMarck Pharmaceuticals Ltd. , Raleigh, N.C.   Product: BIO-11006 inhalation Solution   Business: Pulmonary   Molecular target: NA   Description: Inhibitor of pulmonary inflammation and mucus secretion...
Items per page:
1 - 6 of 6